Respiratorius Project Portfolio
VAL001 has shown clearly promising experimental and clinical data against diseases such as diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin’s lymphoma.
The Company has successfully completed a phase I/IIa study that was conducted at Skåne University Hospital in Lund, Uppsala University Hospital, and Norrland University Hospital in Umeå.
A compound series with a favorable safety profile for which a patent application was recently submitted, has anti-inflammatory and bronchodilatory properties equivalent to those of RESP1000 and RESP2000, but is completely outside these compound series with respect to patents.
The project is in a preclinical phase and is the company’s prioritized project for development of new medications for treatment of COPD and severe asthma.
A compound series of drug candidates with bronchodilatory and anti-inflammatory properties under development to enable treatment of both COPD and asthma.
The project is in preclinical phase and in 2014 a license and collaboration agreement was signed with Cadila Pharmaceuticals Ltd. for preclinical and clinical development of selected drug candidates from the RESP1000 series.
A series of new chemical substances, completely different from RESP1000, that have bronchodilatory properties and the potential to be developed into drugs for treatment of COPD and severe asthma.
The RESP2000 compound series contains substances that affect the mitochondria (in simple terms, the cellular energy sources). In addition, certain exploratory studies will be conducted for other indications. This project is currently in early preclinical phase.
A project aimed at diagnosing conditions such as cardiovascular diseases using PET imaging. The patent-protected RESP3000 compound series represents a further development of the RESP2000 compound series.
Respiratorius has completed a study of RES3105, the selected candidate from the compound series, with promising results.
Signed contract during second quarter of 2019
… with Partner International Inc, to complete the exit of VAL001. Partner International is tasked with working with previously identified candidates and seeking additional stakeholders, with the aim of signing an advantageous contract as soon as possible.
Board of Directors and CEO
A competent team with extensive experience in both business development and commercialization of research findings as well as strong scientific background in relevant areas complemented with knowledge in clinical development and design of clinical trials.
Niklas Prager
Chairman of the Board
Niklas Prager has an MBA from Handelshögskolan (the Stockholm School of Economics) and has since gained extensive experience in company management, board work and investment. Niklas Prager’s career has included CEO of the Swedish division of pharmaceutical company Pfizer and several other CEO positions, including CEO of Medivir AB.
Peter Buhl Jensen
Board Member
Peter Buhl Jensen has an MD and DMSc from the University of Copenhagen. Peter Buhl Jensen has a strong combination of commercial and medical experience, primarily in the development of cancer drugs. As a serial entrepreneur with broad experience in the life science sector, Peter is the founder of TopoTarget, Oncology Venture, Medical Prognosis Institute and several other successful companies.
Johan Drott
CEO
Johan has an extensive experience in senior positions in medical device and pharmaceutical companies with a focus on research, business development and commercialization of research findings.
Kristina Drott
Board member
Kristina is associate professor at the Faculty of Medicine, Lund University and senior consultant of lymphoma oncology at Skåne University Hospital.
Ingemar Kihlström
Board member
Ingemar has a background from R&D within Astra AB och Pharmacia AB and also from the financial industry (Swedbank, Aros Securities och ABG Sundal Collier).
Anna Törner
Board member
Anna Törner has long experience in drug development with a focus on regulatory strategies, from pharmaceutical companies and medicines agencies. Pharmacist and master’s degree in mathematical statistics. PhD in medical sciences from the Karolinska Institute
CEO and board member of Scandinavian Development Services AB.
